In collaboration with the National Cancer Institute (NCI) and SEER program, this study aimed to examine the effect of 31-GEP testing on survival outcomes and confirm the prognostic ability of the 31-GEP at the population level.

The DecisionDx-Melanoma 31-gene expression profile (31-GEP) test is validated to classify cutaneous malignant melanoma (CM) patient risk of recurrence, metastasis, or death as low (Class 1A), intermediate (Class 1B/2A), or high (Class 2B).

SEER cancer registries linked CM cases diagnosed from 2016-2018 to data for patients with Stage I-III CM tested with 31-GEP (n=4,687). To assess if patients tested with the 31-GEP had higher survival rates than untested patients, a cohort of 31-GEP tested patients (n=3,258) with complete matching data available was matched to a cohort of non-31-GEP tested patients (n=9,774) by 11 covariates in a 1:3 ratio.

DecisionDx-Melanoma independently risk stratified patients according to their risk of dying from melanoma, consistent with previously published retrospective and prospective studies.